Standard measures

Our 73 standard measures compare performance across England. This is the measure where NHS Humber and North Yorkshire Integrated Care Board has the greatest potential for improvement. View all 73 measures...

NHS low priority measures

These are measures about low-value items which NHS England says should not routinely prescribed in primary care. This is the ranking of NHS Humber and North Yorkshire Integrated Care Board for all low-value items combined. View the 24 measures...

You can browse all of our measures by topic: Antimicrobial Stewardship (10), Cardiovascular system (11), Central Nervous system (3), Cost Saving (33), Diabetes (5), Efficacy (18), Erectile Dysfunction (1), Eye (1), Gastrointestinal system (1), Generic prescribing (2), Greener NHS (3), Infections (11), NHS England - items which should not routinely be prescribed in primary care (24), Mental Health (5), NICE (24), Nutrition (4), Opioids (5), National medicines optimisation opportunities (10), Pain (13), Mentioned in Papers (2), Reproductive system (1), Respiratory (4), Retired measures (0), Safety (25)

This ICB page is a new feature. We have more data for individual Sub-ICB Locations and practices, and for the whole of England (such as our price-per-unit tool, ghost-branded generics, more email alerts, etc).

Price concessions cost

We estimate that in November 2024 price concessions for out-of-stock medicines will cost NHS Humber and North Yorkshire Integrated Care Board an additional
£201,021

See the full breakdown of this estimate, view costs for other months, and sign up for alerts on the price concessions dashboard.

Sign up for alerts or updates

Get monthly alerts highlighting where you are an outlier, or have suddenly changed (example).

Looking for more data?

Try our Analyse form which allows you run custom analyses on prescribing data for this ICB, or view high-level prescribing trends.

OpenPrescribing Labs

Our Labs page is where we develop experimental new approaches to analysing data. All data and charts on the Labs should be treated cautiously. Our experimental Lab tools automatically identify areas that may be of interest to advanced users of OpenPrescribing, however not all charts presented may be relevant to clinical practice.
To view our first Labs prototype prescribing outlier dashboard click here

Feedback